HomePrice trends

12-month pricing data

GLP-1 price trends

GLP-1 telehealth prices fell roughly 25–40% over the past 12 months as compounded semaglutide entered the market and Eli Lilly launched direct-to-consumer Zepbound vials. Below: every tracked provider's starting monthly price plotted month-over-month, sourced from public price pages, manufacturer promotions, and our monthly editorial checks. Refreshed monthly.

Providers tracked

0

Months of history

0

Avg price change

0%

Biggest drop

—

All providers, last 12 months

How we track these prices

  • Monthly snapshot. First Sunday of each month, we visit each provider site and log the starting price for new patients.
  • Self-pay only. All prices are self-pay starting prices. Insurance-covered tiers are typically $0–$50 with PA and not captured here.
  • Inline notes for shifts. When a price changes month-over-month, we record the likely driver (savings card launch, LillyDirect impact, shortage premium) on the per-provider chart.
  • Affiliate independence. Editorial data collection is independent of commission rates. Provider rankings reflect price + ratings + coverage, never affiliate payout.

Cost vs efficacy

Which GLP-1 gives you the most loss per dollar?

Upper-left is the efficiency frontier: more weight loss for less monthly spend. Off-label T2D medications fall here because they target the same receptor at lower retail prices.

0%5%10%15%20%25%$0$250$500$750$1000$1250$1500Average monthly cash cost (USD)Mean weight loss (% body weight)WegovyZepboundSaxendaOzempic (off-label)Mounjaro (off-label)Rybelsus 14mg (off-label)Compounded sema (503A)
  • Obesity-approved
  • T2D label (off-label obesity use)
  • Compounded (503A)

Weight regain after discontinuation

What happens if you stop GLP-1 therapy

Pivotal trials randomized stable-on-drug patients to either continue or switch to placebo at week 20. Most regained two-thirds of their loss within 12 months. Continued therapy kept losing weight through the same window.

-20%-15%-10%-5%0%5%10%Wk 0Wk 12Wk 24Wk 36Wk 52
  • Semaglutide continued (STEP-4) — kept losing through week 52
  • Switched to placebo (semaglutide) — regained ⅔ by week 52
  • Switched to placebo (tirzepatide, SURMOUNT-4)

Sources: STEP-4 (JAMA 2021;325:1414), SURMOUNT-4 (NEJM 2024). Percentages are mean change from initial trial baseline, not from week-20 randomization point.